Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

664 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Tissue- and liquid-biopsy based NGS profiling in advanced non-small-cell lung cancer in a real-world setting: the IMMINENT study.
Sposito M, Belluomini L, Nocini R, Insolda J, Scaglione IM, Menis J, Simbolo M, Lugini A, Buzzacchino F, Verderame F, Spinnato F, Aprile G, Calvetti L, Occhipinti M, Marinelli D, Veccia A, Lombardo F, Soto Parra HJ, Ferraù F, Savastano C, Porta C, Pradelli L, Sicari E, Castellani S, Malapelle U, Novello S, Bria E, Pilotto S, Milella M. Sposito M, et al. Among authors: milella m. Front Oncol. 2024 Jul 9;14:1436588. doi: 10.3389/fonc.2024.1436588. eCollection 2024. Front Oncol. 2024. PMID: 39045557 Free PMC article.
Antibody-drug conjugates (ADCs) targeting TROP-2 in lung cancer.
Belluomini L, Avancini A, Sposito M, Milella M, Rossi A, Pilotto S. Belluomini L, et al. Among authors: milella m. Expert Opin Biol Ther. 2023 Jul-Dec;23(11):1077-1087. doi: 10.1080/14712598.2023.2198087. Epub 2023 Apr 3. Expert Opin Biol Ther. 2023. PMID: 36995069 Review.
Immune checkpoint blockade therapy mitigates systemic inflammation and affects cellular FLIP-expressing monocytic myeloid-derived suppressor cells in non-progressor non-small cell lung cancer patients.
Adamo A, Frusteri C, Pilotto S, Caligola S, Belluomini L, Poffe O, Giacobazzi L, Dusi S, Musiu C, Hu Y, Wang T, Rizzini D, Vella A, Canè S, Sartori G, Insolda J, Sposito M, Incani UC, Carbone C, Piro G, Pettinella F, Qi F, Wang D, Sartoris S, De Sanctis F, Scapini P, Dusi S, Cassatella MA, Bria E, Milella M, Bronte V, Ugel S. Adamo A, et al. Among authors: milella m. Oncoimmunology. 2023 Sep 14;12(1):2253644. doi: 10.1080/2162402X.2023.2253644. eCollection 2023. Oncoimmunology. 2023. PMID: 37720688 Free PMC article.
Time to strategy failure and treatment beyond progression in pretreated metastatic renal cell carcinoma patients receiving nivolumab: post-hoc analysis of the Meet-URO 15 study.
Murianni V, Signori A, Buti S, Rebuzzi SE, Bimbatti D, De Giorgi U, Chiellino S, Galli L, Zucali PA, Masini C, Naglieri E, Procopio G, Milella M, Fratino L, Baldessari C, Ricotta R, Mollica V, Sorarù M, Tudini M, Prati V, Malgeri A, Atzori F, Di Napoli M, Caffo O, Spada M, Morelli F, Prati G, Nolè F, Vignani F, Cavo A, Lipari H, Roviello G, Catalano F, Damassi A, Cremante M, Rescigno P, Fornarini G, Banna GL. Murianni V, et al. Among authors: milella m. Front Oncol. 2024 Feb 12;14:1307635. doi: 10.3389/fonc.2024.1307635. eCollection 2024. Front Oncol. 2024. PMID: 38410103 Free PMC article.
Prognostic impact of Interleukin-8 levels in lung cancer: A meta-analysis and a bioinformatic validation.
Belluomini L, Cesta Incani U, Smimmo A, Avancini A, Sposito M, Insolda J, Mariangela Scaglione I, Gattazzo F, Caligola S, Adamo A, Conciatori F, Bazzichetto C, Ugel S, Giannarelli D, Pilotto S, Milella M. Belluomini L, et al. Among authors: milella m. Lung Cancer. 2024 Aug;194:107893. doi: 10.1016/j.lungcan.2024.107893. Epub 2024 Jul 14. Lung Cancer. 2024. PMID: 39008934 Free article.
Exploring the Association between Health-Related Physical Fitness and Quality of Life in Patients with Cancer: A Cross-Sectional Study.
Borsati A, Giannarelli D, Belluomini L, Ciurnelli C, Colonna A, D'Amico I, Daniele A, Del Bianco N, Toniolo L, Trestini I, Tregnago D, Insolda J, Sposito M, Lanza M, Milella M, Schena F, Pilotto S, Avancini A. Borsati A, et al. Among authors: milella m. Healthcare (Basel). 2024 Aug 17;12(16):1643. doi: 10.3390/healthcare12161643. Healthcare (Basel). 2024. PMID: 39201201 Free PMC article.
Body composition derangements in lung cancer patients treated with first-line pembrolizumab: A multicentre observational study.
Trestini I, Belluomini L, Dodi A, Sposito M, Caldart A, Kadrija D, Pasqualin L, Riva ST, Scaglione IM, Tregnago D, Avancini A, Insolda J, Confortini L, Casali M, Menis J, Vita E, Cintoni M, Todesco M, Milanese G, Sperduti I, D'Onofrio M, Infante M, Tiseo M, Mele MC, Tortora G, Milella M, Bria E, Pilotto S. Trestini I, et al. Among authors: milella m. J Cachexia Sarcopenia Muscle. 2024 Dec;15(6):2349-2360. doi: 10.1002/jcsm.13568. Epub 2024 Oct 22. J Cachexia Sarcopenia Muscle. 2024. PMID: 39439222 Free PMC article.
Analyses of tumor microenvironment in patients with advanced renal cell carcinoma receiving immunotherapy (Meet-URO 18 study).
Catalano F, Brunelli M, Signori A, Rescigno P, Buti S, Galli L, Spada M, Masini C, Galuppini F, Vellone VG, Gaggero G, Maruzzo M, Merler S, Vignani F, Cavo A, Bimbatti D, Milella M, Dei Tos AP, Sbaraglia M, Murianni V, Damassi A, Cremante M, Maffezzoli M, Llaja Obispo MA, Banna GL, Fornarini G, Rebuzzi SE. Catalano F, et al. Among authors: milella m. Future Oncol. 2024;20(21):1495-1503. doi: 10.2217/fon-2023-1068. Epub 2024 Jun 12. Future Oncol. 2024. PMID: 38682738
Analyses of tumor microenvironment in patients with advanced renal cell carcinoma receiving immunotherapy (Meet-URO 18 study).
Catalano F, Brunelli M, Signori A, Rescigno P, Buti S, Galli L, Spada M, Masini C, Galuppini F, Vellone VG, Gaggero G, Maruzzo M, Merler S, Vignani F, Cavo A, Bimbatti D, Milella M, Dei Tos AP, Sbaraglia M, Murianni V, Damassi A, Cremante M, Maffezzoli M, Llaja Obispo MA, Banna GL, Fornarini G, Rebuzzi SE. Catalano F, et al. Among authors: milella m. Future Oncol. 2024 May 3:1-19. doi: 10.1080/14796694.2024.2340960. Online ahead of print. Future Oncol. 2024. PMID: 38861289
Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 study.
Massari F, Santoni M, Takeshita H, Okada Y, Tapia JC, Basso U, Maruzzo M, Scagliarini S, Büttner T, Fornarini G, Myint ZW, Galli L, Souza VC, Pichler R, De Giorgi U, Gandur N, Lam ET, Gilbert D, Popovic L, Grande E, Mammone G, Berardi R, Crabb SJ, Kemp R, Molina-Cerrillo J, Freitas M, Luz M, Iacovelli R, Calabrò F, Tural D, Atzori F, Küronya Z, Chiari R, Campos S, Caffo O, Fay AP, Kucharz J, Zucali PA, Rinck JA, Zeppellini A, Bastos DA, Aurilio G, Mota A, Trindade K, Ortega C, Sade JP, Rizzo M, Fiala O, Vau N, Giannatempo P, Barillas A, Monteiro FSM, Dauster B, Mennitto A, Nogueira L, de Carvalho Fernandes R, Seront E, Aceituno LG, Grillone F, Cutuli HJ, Fernandez M, Bassanelli M, Kopp RM, Roviello G, Abahssain H, Procopio G, Milella M, Kopecky J, Martignetti A, Messina C, Caitano M, Inman E, Kanesvaran R, Herchhorn D, Santini D, Bamias A, Bisonni R, Mosca A, Morelli F, Maluf F, Soares A, Nunes F, Pinto A, Zgura A, Incorvaia L, Ansari J, Zabalza IO, Landmesser J, Rizzo A, Mollica V, Marchetti A, Rosellini M, Sorgentoni G, Battelli N, Buti S, Porta C, Bellmunt J. Massari F, et al. Among authors: milella m. Cancer Immunol Immunother. 2024 Apr 18;73(6):106. doi: 10.1007/s00262-024-03682-w. Cancer Immunol Immunother. 2024. PMID: 38634928 Free PMC article.
664 results